All News

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Ointment USP, (Augmented), 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Diprolene® Ointment manufactured by Organon LLC. Betamethasone Dipropionate Ointment are […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. Aurobindo Pharma’s Desmopressin Acetate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), DDAVP Tablets manufactured by Ferring Pharmaceuticals, Inc. Desmopressin […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray. Aurobindo Pharma’s Mometasone Furoate Monohydrate Nasal Spray, are an AB-rated generic equivalent to the reference listed drug (RLD), Nasonex Nasal Spray manufactured by Organon LLC. […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fingolimod Capsules, 0.5 mg. Aurobindo Pharma’s Fingolimod Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Gilenya Capsules manufactured by Novartis Pharmaceuticals Corporation. Fingolimod Capsules are indicated for: The […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Aurobindo Pharma’s Mycophenolic Acid Delayed-Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Myfortic Delayed-Release Tablets manufactured by […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolate Mofetil Tablets USP, 500 mg. Aurobindo Pharma’s Mycophenolate Mofetil Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Cellcept Tablets manufactured by Roche Palo Alto LLC. Mycophenolate Mofetil […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg. Aurobindo Pharma’s Atorvastatin Calcium Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), LIPITOR® Tablets manufactured […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deflazacort Tablets, 6mg, 18mg, 30mg, & 36mg. Aurobindo Pharma’s Deflazacort Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), EMFLAZA® Tablets manufactured by PTC Therapeutics Inc.  Deflazacort Tablets are […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Isotretinoin Capsules USP, 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg. Aurobindo Pharma’s Isotretinoin Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Absorica® […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lacosamide Oral Solution USP, 10 mg/mL. Aurobindo Pharma’s Lacosamide Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VIMPAT® Oral Solution manufactured by UCB, Inc. Lacosamide Oral Solution […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Enalapril Maleate Oral Solution, 1 mg/mL. Aurobindo Pharma’s Enalapril Maleate Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Epaned® Oral Solution manufactured by Azurity Pharmaceuticals, Inc. Enalapril […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolate Mofetil Capsules USP, 250 mg. Aurobindo Pharma’s Mycophenolate Mofetil Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), CellCept Capsules manufactured by Roche Palo Alto LLC. Mycophenolate Mofetil […]